{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T13:54:54Z","timestamp":1723298094504},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,2]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>It has been suggested that a plasma trough concentration of aripiprazole plus its active metabolite, dehydroaripiprazole of 225 ng\/mL is a threshold for a good therapeutic response in the treatment of acutely exacerbated patients with schizophrenia. The present study investigated whether or not an optimal dose of aripiprazole could be predicted from these concentrations at week 1.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The subjects were 26 inpatients with schizophrenia, who received aripiprazole once a day for 3 weeks. The daily doses were 12 mg for the first week and 24 mg for the next 2 weeks. No other drugs except biperiden and flunitrazepam were coadministered. Blood samples were taken at weeks 1 and 3 after the treatment. Plasma concentrations of aripiprazole and dehydroaripiprazole were measured using liquid chromatography with mass-spectrometric detection.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>There was a significant linear relationship between the plasma concentrations of aripiprazole plus dehydroaripiprazole at weeks 1 (<jats:italic toggle=\"yes\">x<\/jats:italic>) and 3 (<jats:italic toggle=\"yes\">y<\/jats:italic>) (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). Regression equation was <jats:italic toggle=\"yes\">y<\/jats:italic> = 2.580<jats:italic toggle=\"yes\">x<\/jats:italic> + 34.86 (R<jats:sup>2<\/jats:sup> = 0.698). Based on the equation, a nomogram to estimate an optimal dose of aripiprazole could be constructed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The present study suggests that an optimal dose of aripiprazole for the treatment of patients with schizophrenia can be predicted from the plasma concentrations of the sum of the 2 compounds at week 1.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000358","type":"journal-article","created":{"date-parts":[[2016,11,18]],"date-time":"2016-11-18T02:33:36Z","timestamp":1479436416000},"page":"62-65","source":"Crossref","is-referenced-by-count":6,"title":["Prediction of an Optimal Dose of Aripiprazole in the Treatment of Schizophrenia From Plasma Concentrations of Aripiprazole Plus Its Active Metabolite Dehydroaripiprazole at Week 1"],"prefix":"10.1097","volume":"39","author":[{"given":"Goyo","family":"Nagai","sequence":"first","affiliation":[{"name":"Neuropsychiatry and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Mihara","sequence":"additional","affiliation":[{"name":"Neuropsychiatry and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akifumi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Neuropsychiatry and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Nemoto","sequence":"additional","affiliation":[{"name":"Neuropsychiatry and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoko","family":"Kagawa","sequence":"additional","affiliation":[{"name":"Neuropsychiatry and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Neuropsychiatry and"},{"name":"Hospital Pharmacy, Graduate School of Medicine, University of the Ryukyus, Nishihara, Okinawa, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Kondo","sequence":"additional","affiliation":[{"name":"Neuropsychiatry and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2165\/00003495-200464150-00010","article-title":"Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder","volume":"64","author":"Harrison","year":"2004","journal-title":"Drugs"},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.eurpsy.2007.03.002","article-title":"A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients. Schizophrenia Trial of Aripiprazole (STAR) study","volume":"22","author":"Kerwin","year":"2007","journal-title":"Eur Psychiatry."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1440-1819.2012.02391.x","article-title":"Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptors and cytochrome P450 2D6 in Japanese patients with schizophrenia","volume":"66","author":"Nagai","year":"2012","journal-title":"Psychiatry Clin Neurosci."},{"key":"R5-20230814","first-page":"1","article-title":"Improvement in antipsychotic-induced hyperprolactinemia with addition of aripiprazole in schizophrenic patients","volume":"1","author":"Mihara","year":"2011","journal-title":"Clin Neuropsychopharmacol Ther."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"612","DOI":"10.2174\/138920007781368908","article-title":"N-dealkylation of arylpiperazine derivatives: disposition and metabolism of the 1-aryl-piperazines formed","volume":"8","author":"Caccia","year":"2007","journal-title":"Curr Drug Metab."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1080\/15622970701361255","article-title":"Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects","volume":"9","author":"Kirschbaum","year":"2008","journal-title":"World J Biol Psychiatry."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1097\/JCP.0b013e3182356255","article-title":"Aripiprazole and dehydroaripiprazole plasma concentrations and clinical responses in patients with schizophrenia","volume":"31","author":"Li","year":"2011","journal-title":"J Clin Psychopharmacol."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2133\/dmpk.20.55","article-title":"Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic aripiprazole","volume":"20","author":"Kubo","year":"2005","journal-title":"Drug Metab Pharmacokinet."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/FTD.0b013e3182031021","article-title":"Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia","volume":"33","author":"Suzuki","year":"2011","journal-title":"Ther Drug Monit."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/FTD.0000000000000070","article-title":"Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia","volume":"36","author":"Suzuki","year":"2014","journal-title":"Ther Drug Monit."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/FTD.0b013e31824a31e6","article-title":"Effects of paroxetine on plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia","volume":"34","author":"Nemoto","year":"2012","journal-title":"Ther Drug Monit."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1055\/s-0034-1372644","article-title":"Effects of escitalopram on plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients","volume":"47","author":"Nemoto","year":"2014","journal-title":"Pharmacopsychiatry"},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/FTD.0000000000000082","article-title":"Lack of correlation between the steady-state plasma concentrations of aripiprazole and haloperidol in Japanese patients with schizophrenia","volume":"36","author":"Nakamura","year":"2014","journal-title":"Ther Drug Monit."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/FTD.0b013e3181b6326a","article-title":"Pharmacokinetic and pharmacodynamic interactions between carbamazepine and aripiprazole in patients with schizophrenia","volume":"31","author":"Nakamura","year":"2009","journal-title":"Ther Drug Monit."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.schres.2009.01.011","article-title":"Aripiprazole brain concentration is altered in P-glycoprotein deficient mice","volume":"110","author":"Wang","year":"2009","journal-title":"Schizophr Res."},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.neuropharm.2010.06.010","article-title":"Pharmacokinetics of acute and sub-acute aripiprazole in P-glycoprotein deficient mice","volume":"59","author":"Kirschbaum","year":"2010","journal-title":"Neuropharmacology"},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00004714-199602000-00008","article-title":"Prediction of haloperidol steady-state levels in plasma after a single test dose","volume":"16","author":"Javaid","year":"1996","journal-title":"J Clin Psychopharmacol."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00004714-199006000-00010","article-title":"Pharmacokinetic protocol for predicting plasma haloperidol concentrations","volume":"10","author":"Miller","year":"1990","journal-title":"J Clin Psychopharmacol."},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2133\/dmpk.22.358","article-title":"Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism","volume":"22","author":"Kubo","year":"2007","journal-title":"Drug Metab Pharmacokinet."},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jchromb.2005.06.023","article-title":"Development and validation of an LC-MS\/MS method for the quantitative determination of aripiprazole and its main metabolite, OPC-14857, in human plasma","volume":"822","author":"Kubo","year":"2005","journal-title":"J Chromatogr B."},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201702000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:01:08Z","timestamp":1692050468000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201702000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000358","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]}}}